ABSTRACT
OBJECTIVE@#To investigate the transcriptome profile of genital tubercles (GTs) in male SD rats and explore the mechanism of hypospadias induced by Di (2-ethylhexyl) phthalate (DEHP).@*METHODS@#Forty time-pregnant SD rats were randomly divided into 4 equal groups, namely GD16 group and GD19 group (in which the male GTs were collected on gestation day[GD]16 and GD19 for RNA-seq, respectively), control group and DEHP exposure group (with administration of oil and 750 mg/kg DEHP by gavage from GD12 to GD19, respectively).In the control and DEHP exposure groups, the GTs were collected from the male fetuses on GD19.5, and scanning electron microscopy and HE staining were used to observe the morphological changes.The differentially expressed genes (DEGs) in the GTs were screened using lllumina HiSeq 2000 followed by GO and KEGG enrichment analyses to characterize the transcriptome profile.Immunofluorescence assay was performed to verify the DEGs (Mafb) identified by RNA-seq results.Immunofluorescence assay and Western blotting were used to examine the expression levels of Mafb in the penile tissue.@*RESULTS@#A total of 1360 DEGs were detected in the GTs between GD16 group and GD19 group by RNA-seq.Among these genes, 797 were up-regulated and 563 were down-regulated.These DEGs were mainly enriched in the cell adhesion plaque signaling pathway, axon guidance signaling pathway, and extracellular matrix receptor signaling pathway.Compared with that in GD16 group, Mafb was significantly up-regulated in GD19 group, which was consistent with the sequencing results.Mafb and β-catenin were significantly down-regulated in DEHP-exposed group compared with the control group ( < 0.01).@*CONCLUSIONS@#Mafb expression increases progressively with the development of GTs in male SD rats.DEHP exposure causes significant down-regulation of Mafb and β-catenin, suggesting that β-catenin signaling pathway that affects Mafb is related to DEHP-induced hypospadias in SD rats.
Subject(s)
Animals , Female , Humans , Male , Pregnancy , Rats , Diethylhexyl Phthalate , Gene Expression Profiling , Hypospadias , MafB Transcription Factor , Oncogene Proteins , Phthalic Acids , Rats, Sprague-DawleyABSTRACT
Farnesoid X receptor (FXR) and related pathways are involved in the therapeutic effect of sleeve gastrectomy for overweight or obese patients with diabetes mellitus. This study aimed to investigate the mechanism of FXR expression regulation during the surgical treatment of obese diabetes mellitus by sleeve gastrectomy. Diabetic rats were established by combined streptozotocin and high-fat diet induction. Data collection included body weight, chemical indexes of glucose and lipid metabolism, liver function, and the expression levels of musculoaponeurotic fibrosarcoma oncogene family B (MAFB), FXR, and related genes induced by sleeve gastrectomy. Chang liver cells overexpressing MAFB gene were established to confirm the expression of related genes. The binding and activation of FXR gene by MAFB were tested by Chip and luciferase reporter gene assays. Vertical sleeve gastrectomy induced significant weight loss and decreased blood glucose and lipids in diabetic rat livers, as well as decreased lipid deposition and recovered lipid function. The expression of MAFB, FXR, and FXR-regulated genes in diabetic rat livers were also restored by sleeve gastrectomy. Overexpression of MAFB in Chang liver cells led to FXR gene expression activation and the alteration of multiple FXR-regulated genes. Chip assay showed that MAFB could directly bind with FXR promoter, and the activation of FXR expression was confirmed by luciferase reporter gene analysis. The therapeutic effect of sleeve gastrectomy for overweight or obese patients with diabetes mellitus was mediated by activation of FXR expression through the binding of MAFB transcription factor.
Subject(s)
Animals , Male , Rats , Oncogene Proteins/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Diabetes Mellitus, Experimental/metabolism , MafB Transcription Factor/metabolism , Gastrectomy/methods , Obesity/surgery , Gene Expression Regulation , Blotting, Western , Rats, Sprague-Dawley , Oncogene Proteins/genetics , Receptors, Cytoplasmic and Nuclear/genetics , Reverse Transcriptase Polymerase Chain Reaction , MafB Transcription Factor/genetics , Lipid Metabolism , Liver/metabolism , Obesity/metabolismABSTRACT
Aminoglycoside antibiotics, due to their strong antibacterial effects and broad antimicrobial spectra, have been very commonly used in clinical practice in the past half century. However, aminoglycoside antibiotics manifest severe ototoxicity and nephrotoxicity, and are one of top factors in hearing loss. In this study, three members of the aminoglycoside antibiotics family, gentamycin, neomycin and streptomycin, were chosen as the representatives to be investigated for their toxicity to the embryonic development and the larva hair cells in zebrafish, and also to their target genes associated with hearing-related genes. The results showed that: (1) the lethal effect of all three drugs demonstrated a significant dependence on concentration, and the severity order of the lethal effect was streptomycin > neomycin > gentamycin; (2) all the three drugs caused the larva trunk bending in resting state at 5 dpf (day past fertilization), probably due to their ototoxicity in the physical imbalance and postural abnormalities; (3) impairment and reducing of the hair cells were observed in all three cases of drug treatment; (4) four genes, eya1, val, otx2 and dlx6a, which play an important role in the development of hearing organs, showed differential and significant decrease of gene expression in a drug concentration-dependent manner. This study for the first time reports the relevance between the expression of hearing genes and the three ototoxic antibiotics and also proved the feasibility of establishing a simple, accurate, intuitive and fast model with zebrafish for the detection of drug ototoxicity.
Subject(s)
Animals , Aminoglycosides , Toxicity , Anti-Bacterial Agents , Toxicity , Embryonic Development , Gene Expression Regulation , Gentamicins , Toxicity , Hair Cells, Auditory , Cell Biology , Hearing Disorders , Genetics , Metabolism , Homeodomain Proteins , Metabolism , Intracellular Signaling Peptides and Proteins , Metabolism , Larva , Lateral Line System , MafB Transcription Factor , Metabolism , Models, Animal , Neomycin , Toxicity , Nerve Tissue Proteins , Metabolism , Nuclear Proteins , Metabolism , Otx Transcription Factors , Metabolism , Protein Synthesis Inhibitors , Toxicity , Protein Tyrosine Phosphatases , Metabolism , Streptomycin , Toxicity , Zebrafish , Embryology , Zebrafish Proteins , MetabolismABSTRACT
This study was aimed to quantitatively detect the level of maf-b mRNA in leukemia patients and evaluate its clinical significance. Real-time fluorescence quantitative PCR was used to detect the relative expression level of maf-b mRNA. The expression change of maf-b mRNA in various types of leukemia was analyzed. Then, the relationship of maf-b mRNA expression with laboratory index and the response to chemotherapy was analyzed. The results showed that maf-b mRNA expression level in acute myeloid leukemia (AML) patients was lower than that in normal group (p<0.01) and positively correlated with white blood cell count (p<0.01) and the expression of CD34 (p<0.01). There was no correlation between maf-b mRNA expression level and chemotherapy response in AML patients except for acute promyelocytic leukemia (APL). Maf-b mRNA expression levels in acute lymphoid leukemia (ALL) and chronic myeloid leukemia (CML) patients were also lower than that in normal group (p<0.01). It is concluded that there is low expression of maf-b gene in AML patients. Abnormal expression of maf-b correlates with abnormal proliferation of AML cells, which may be a new prognostic factor for AML.
Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Male , Middle Aged , Young Adult , Case-Control Studies , Cell Proliferation , Leukemia , Genetics , Pathology , Leukemia, Myeloid, Acute , Genetics , Pathology , MafB Transcription Factor , Genetics , RNA, Messenger , GeneticsABSTRACT
Genetic alterations have been recognized as an important event in the carcinogenesis of gastric cancer (GC). We conducted high resolution bacterial artificial chromosome array-comparative genomic hybridization, to elucidate in more detail the genomic alterations, and to establish a pattern of DNA copy number changes with distinct clinical variables in GC. Our results showed some correlations between novel amplified or deleted regions and clinical status. Copy-number gains were frequently detected at 1p, 5p, 7q, 8q, 11p, 16p, 20p and 20q, and losses at 1p, 2q, 4q, 5q, 7q, 9p, 14q, and 18q. Losses at 4q23, 9p23, 14q31.1, or 18q21.1 as well as a gain at 20q12 were correlated with tumor-node-metastasis tumor stage. Losses at 9p23 or 14q31.1 were associated with lymph node status. Metastasis was determined to be related to losses at 4q23 or 4q28.2, as well as losses at 4q15.2, 4q21.21, 4q 28.2, or 14q31.1, with differentiation. One of the notable aspects of this study was that the losses at 4q or 14q could be employed in the evaluation of the metastatic status of GC. Our results should provide a potential resource for the molecular cytogenetic events in GC, and should also provide clues in the hunt for genes associated with GC.
Subject(s)
Middle Aged , Male , Humans , Female , Aged, 80 and over , Aged , Adult , Stomach Neoplasms/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods , Receptors, Thyrotropin/genetics , Nucleic Acid Hybridization/methods , Neoplasm Staging , MafB Transcription Factor/genetics , Lymphatic Metastasis/genetics , Genome, Human/genetics , Gene Expression Regulation, Neoplastic , Chromosomes, Human, Pair 20/genetics , Chromosomes, Human, Pair 14/genetics , Chromosome AberrationsABSTRACT
<p><b>BACKGROUND</b>In previous work, we suggested that some 2-aminosteroids inhibited proliferation and induced differentiation of both human and murine leukemia cells. Here, we reported the actions of another new 2-aminosteroid designated as H89712 on human leukemia cells.</p><p><b>METHODS</b>Cell colony counting and MTT assay were used to determine proliferation. Cell morphology, histochemical staining, UV detection and cytometry were used to determine differentiation. RT-PCR was used to detect gene expression. Standard statistical method was used to analyze data.</p><p><b>RESULTS</b>H89712 inhibited proliferation of HL-60 leukemia cells and the inhibition percentage in MTT assay was 18% at the dose of 10(-8) mol/L and 65% at the dose of 10(-5) mol/L, respectively. The inhibition for HL-60 in colony assay was 23% at the dose of 10(-8) mol/L and 96% at the dose of 10(-5) mol/L, respectively. H89712 also induced HL-60 cells toward macrophage-like differentiation. It was verified by flow cytometry that the percentage of positive CD14 expression in differentiated HL-60 cells was about 9 times higher than that of the control at the dose of 10(-8) mol/L and 20 times higher than that of the control at the dose of 10(-5) mol/L respectively, and this action involved upregulation of MafB gene in HL-60 leukemia cells. On the other hand, H89712 inhibited proliferation of K562 leukemia cells and the inhibition of K562 leukemia cells in MTT assay was shown by 34% at the dose of 10(-8) mol/L and 88% at the dose of 10(-5) mol/L respectively. The inhibition of K562 leukemia cells in colony assay was 53% at the dose of 10(-8) mol/L and 100% at the dose of 10(-5) mol/L respectively. H89712 also induced K562 cells toward erythroid-like differentiation and it was verified by flow cytometry that the percentage of positive CD71 expression in differentiated K562 cells was about 9 times higher than that of the control at the dose of 10(-8) mol/L and 16 times higher than that of the control at the dose of 10(-5) mol/L respectively. This action was related to upregulation of Egr-1 gene in K562 leukemia cells.</p><p><b>CONCLUSIONS</b>Our results showed the important roles played by MafB in macrophage differentiation and Egr-1 in erythroid differentiation of human myeloid leukemia cells.</p>